Moreover, treatment of FXS patient cells with an inhibitor of DNA methyltransferase 1 (DNMT1), 5-azadeoxycytidine (5-aza-dC), leads to gene reactivation [45]. The gene discussed is DNMT1; the disease is fragile X syndrome.